Diabetes patients on dulaglutide (Trulicity) had better glycemic control and more weight loss if they switched to tirzepatide (Mounjaro) rather than increasing the dose of the earlier-generation GLP-1 ...

Compounded tirzepatide contains the same active ingredient as Mounjaro, but its dosage and some ingredients may differ from Mounjaro. The Food and Drug Administration (FDA) does not regulate the ...

Despite promising adherence and persistence data, tirzepatide dose escalation was slower in the real-world than clinical trials in patients with obesity without T2D. Tirzepatide dose escalation is ...

KELOWNA, BC / ACCESSWIRE / October 9, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce ...

Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like ...

NEW ORLEANS — For people with type 2 diabetes (T2D) inadequately controlled on submaximal dulaglutide (Trulicity) doses, switching to tirzepatide (Mounjaro) produces significantly greater A1c and ...

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 ...

Please provide your email address to receive an email when new articles are posted on . Less than 10% of adults receiving tirzepatide in clinical trials reported a serious adverse event.

By Dr. Priyom Bose, Ph.D. New intracranial recordings show that a distinct neural rhythm in the brain’s reward center surges ...

Patients with poorly controlled type 2 diabetes despite being on dulaglutide had better outcomes if they switched to tirzepatide than if they upped their dulaglutide dose. In this randomized trial, ...